Fact CheckerSign in

NCT07541677Completed

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity

Source: ClinicalTrials.gov · Last updated 27 Oct 2026

Brief summary (registry, in English)

Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%. In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups. The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments. Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.

Status (registry)
Completed
Study type
Observational
Enrollment
160 (actual)
First submitted
11 Aug 2025
Start date
26 May 2025
Primary completion date
31 May 2026
Lead sponsor
Singapore General Hospital
Diseases
Obesity
NCT number
NCT07541677

What you commit to

  • Study type: Observational
  • Participants enrolled: 160
  • From 26 May 2025 to the primary completion date, 31 May 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)

Other illness

  • history of bariatric procedures or surgeries

Other

  • unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
  • pregnant women

Who the study is looking for

  • body mass index ≥ 27.5kg/m2
  • able to provide informed consent.

Age in the registry: 21 years to 100 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Singapore General Hospital
Coordinator of this site? Confirm its status
SingaporeSingaporeUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.